



Published in final edited form as:

*Curr Biol.* 2022 January 10; 32(1): 237–247.e6. doi:10.1016/j.cub.2021.10.049.

## Aurora B phosphorylates Bub1 to promote spindle assembly checkpoint signaling

Babhrubhan Roy<sup>1</sup>, Simon J. Y. Han<sup>1,2</sup>, Adrienne N. Fontan<sup>1,3</sup>, Soubhagyalaxmi Jema<sup>1</sup>, Ajit P. Joglekar<sup>1,\*</sup>

<sup>1</sup>Cell & Developmental Biology, University of Michigan Medical School, 109 Zina Pitcher Pl., Ann Arbor, MI-48109, USA

<sup>2</sup>present address: Medical Scientist Training Program, University of Cincinnati College of Medicine, 3230 Eden Ave, Cincinnati, OH 45267, USA

<sup>3</sup>present address: Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, 455 Main St, Cambridge, MA 02142

### Summary

Accurate chromosome segregation during cell division requires amphitelic chromosome attachment to the spindle apparatus. It is ensured by the combined activity of the Spindle Assembly Checkpoint<sup>1</sup> (SAC), a signaling mechanism that delays anaphase onset in response to unattached chromosomes, and an error correction mechanism that eliminates syntelic attachments<sup>2</sup>. The SAC becomes active when Mps1 kinase sequentially phosphorylates the kinetochore protein Spc105/KNL1 and the signaling proteins that Spc105/KNL1 recruits to facilitate the production of the Mitotic Checkpoint Complex<sup>3–8</sup> (MCC). The error correction mechanism is regulated by the Aurora B kinase, but Aurora B also promotes SAC signaling via indirect mechanisms<sup>9–12</sup>. Here we present evidence that Aurora B kinase activity directly promotes MCC production by working downstream of Mps1 in budding yeast and human cells. Using the ectopic SAC activation (eSAC) system, we find that the conditional dimerization of Aurora B in budding yeast, and an Aurora B recruitment domain in HeLa cells, with either Bub1 or Mad1, but not the phosphodomain of Spc105/KNL1, leads to ectopic MCC production and mitotic arrest<sup>13–16</sup>. Importantly, Bub1 must recruit both Mad1 and Cdc20 for this ectopic signaling activity. These and other data show that Aurora B cooperates with Bub1 to promote MCC production, but only after Mps1 licenses Bub1 recruitment to the kinetochore. This direct involvement of Aurora B in SAC signaling may maintain SAC signaling even after Mps1 activity in the kinetochore is lowered.

\* corresponding author, lead contact: ajitj@umich.edu, Twitter handle: @AjitJoglekar1.

#### Author Contributions

Conceptualization, Methodology, Writing – Original Draft, Writing – Review & Editing, Visualization, and Supervision, B.R. and A.P.J.; Formal Analysis and Investigation, B.R., S.J.Y.H., A.F. S.J. and A.P.J.; Software, Resources, and Funding Acquisition, A.P.J.

#### Declaration of Interests

We declare that no competing interests exist.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## eToc Blurb

The Spindle Assembly Checkpoint (SAC) ensures accurate chromosome segregation during cell division. Roy *et al.* show that the Aurora B kinase phosphorylates the checkpoint protein Bub1 to promote SAC signaling in budding yeast and human cells. Thus, the error correction machinery and the SAC likely cooperate to minimize chromosome missegregation.

## Results & Discussion

### Dissecting the contributions of Bub1 and Mad1 in Mps1-driven Mitotic Checkpoint Complex (MCC) formation

To activate the SAC and delay anaphase onset, unattached kinetochores produce the MCC, which is a complex of four proteins: the ‘closed’ form of Mad2, Cdc20, BubR1, and Bub3. MCC production is licensed by the Mps1 kinase, which sequentially phosphorylates SAC proteins within the kinetochore to promote their recruitment<sup>3–6</sup> (Figure 1A). Cdc20 is recruited by Bub1 and BubR1 through constitutive interactions<sup>17</sup>. SAC proteins recruited interact to produce the MCC. Although Mps1 plays the dominant and essential role in this process, Aurora B kinase activity is also required for maximal signaling<sup>9–11,18–23</sup>. In budding yeast, Aurora B phosphorylates Mad3/BubR1<sup>24</sup>. Whether it phosphorylates other SAC signaling proteins to catalyze MCC production has been difficult to determine, mainly because Mps1 and Aurora B act concurrently within unattached kinetochores. Therefore, to study the effect of Aurora B on SAC proteins, we used the ectopic SAC activation assay or “eSAC”<sup>13</sup>. In this assay, a mitotic kinase domain is conditionally dimerized with a cytosolic phosphodomain of the kinetochore protein Spc105/KNL1 or Bub1<sup>13–16</sup>. The ensuing signaling activity is evident as a mitotic delay.

We first used the eSAC assay to clearly delineate the known Mps1 roles in SAC signaling relying on flow cytometry to quantify the DNA content of yeast cells (Figure 1B). As positive controls, we dimerized Mps1–2xFkbp12 with either ‘MELT’-motif containing fragments of the Spc105 phosphodomain or Bub1 or Bub3 fused to Frb and GFP by adding rapamycin to the growth media (Figure 1B). In all cases, cell populations shifted to 2n ploidy indicating a G2/M arrest<sup>25</sup> (Figure 1B–C, Figure S1A–B, rapamycin panels in red). Cells lacking Mad2 did not arrest following rapamycin treatment (Figure 1B, dashed blue panel). Thus, the arrest required a functional SAC.

Bub1 contributes two activities for MCC formation. It recruits Mad1 via its central domain, and in human cells, Cdc20 via a conserved ‘ABBA’ motif<sup>3,5,17,26–28</sup> (Figure 1C). To separate their contributions, we generated *bub1<sup>-abba</sup>* wherein the hydrophobic residues predicted to interface with Cdc20 are mutated<sup>26</sup>. Induced dimerization of Mps1 with *bub1<sup>-abba</sup>* caused a mitotic arrest suggesting that the ABBA motif is dispensable in Mps1-driven signaling (Figure 1C). Consistently, *bub1<sup>-abba</sup>* cells arrested in mitosis following nocodazole treatment (Figure S1C). The fraction of cells escaping the mitotic block was higher compared to wild-type cells indicating that the SAC is weaker (Figure S1C). Mad1-mCherry recruitment to unattached kinetochores in *bub1<sup>-abba</sup>* cells was also ~50% lower<sup>28</sup> (Figure S1D). Bub1-Cdc20 interaction has been difficult to confirm using biochemical methods in HeLa cells<sup>29</sup>. We also could not confirm this interaction in yeast

using immunoprecipitation, yeast two-hybrid assays, or microscopy (data not shown). However, the conservation of the ABBA motif sequence supports our assumption that *bub1*<sup>-abba</sup> cannot bind Cdc20.

Mps1 phosphorylates many sites within the Bub1 central domain to promote the Bub1-Mad1 interaction<sup>3,5,6,28,30</sup>. To find the essential phosphorylatable residues, we generated numerous Bub1 mutants wherein subsets of the phosphorylation sites are non-phosphorylatable (Table S1). Some of these mutants weakened, but did not abolish, SAC signaling (Table S1). Mad1 localization to unattached kinetochores was also diminished, but not abolished, even in those mutants that significantly weakened the SAC (Figure S1D). Consistently, Mps1 dimerization with these phosphomutants led to robust eSAC signaling (Table S1). Finally, we dimerized Mps1 with *bub1*-15A, wherein 15 phosphorylation sites are non-phosphorylatable<sup>3,16</sup>. *bub1*-15A localized to unattached kinetochores in nocodazole-treated cells better than wild-type Bub1. However, it did not activate either SAC or the eSAC (Figure 1C, Figure S1C and S1E, flow cytometry right panel). Thus, eSAC signaling driven by Mps1-Bub1 dimerization requires Bub1-mediated Mad1 recruitment.

In human cells, Mps1 phosphorylates Mad1 to facilitate the formation of Cdc20:C-Mad2<sup>5,6</sup>. Consistently, induced dimerization of Mps1 with Mad1 arrested yeast cells in mitosis. This arrest was not observed in *mad3* cells, indicating that it was mediated by ectopic SAC signaling (Figure 1D). eSAC activity persisted in *spc105-6A* cells, wherein all six MELT motifs in Spc105 are non-phosphorylatable, and in *bub3* cells. Thus, this ectopic SAC activation does not require Bub1 localization to the kinetochore. The latter observation also indicates that the budding yeast MCC can be formed ectopically without Bub3<sup>31</sup>. Consistent with the dispensability of the Bub1 ABBA motif for Mps1-driven eSAC signaling, Mps1-Mad1 dimerization produced a robust mitotic arrest in *bub1*<sup>-abba</sup> cells (Figure 1D). Finally, Mps1 dimerization with *mad1*-4A, wherein residues implicated in the Mad1-Cdc20 interaction are non-phosphorylatable (Figure 1D), did not affect the cell cycle<sup>5,6</sup>. Interestingly, Mps1-Mad1 dimerization did not affect cell cycle progression in cells expressing *bub1*-15A likely because Bub1 scaffolding of Mad1 and Cdc20 is necessary for the ectopic MCC assembly<sup>32,33</sup> (Figure S1F).

MCC formation also requires BubR1, known as Mad3 in budding yeast. In metazoa and fission yeast, BubR1 is recruited to the kinetochore by Bub1<sup>16,34,35</sup>. However, this Bub1-BubR1 interaction is likely not conserved in budding yeast<sup>36</sup>. To confirm this, we fused GFP to the N-terminus of Mad3 (C-terminal fusion of GFP to Mad3 makes it incompetent in SAC signaling, data not shown) and visualized it in nocodazole-treated cells. GFP-Mad3 expressed from the endogenous promoter was undetectable at unattached kinetochores (data not shown). Even when exogenous GFP-Mad3 was significantly overexpressed, it rarely colocalized with unattached kinetochores (Figure 1E and Figure S1G).

These observations suggest the following model for Mps1-driven SAC signaling in budding yeast. As established by previous studies, Mps1 licenses the sequential recruitment of Bub1-Bub3 and Mad1-Mad2 by phosphorylating the MELT motifs and Bub1. ABBA motif in Bub1 contributes to SAC signaling, but it is not essential. Mps1 also phosphorylates Mad1 to promote its interaction with Cdc20, and this is essential for MCC formation. Finally, the

lack of GFP-Mad3 localization suggests that unattached yeast kinetochores mainly catalyze Cdc20-C-Mad2 formation.

### Testing whether Aurora B/Ipl1 kinase activity promotes MCC formation

The Aurora B kinase, known as Ipl1 in budding yeast, is implicated in SAC signaling. Ipl1 is positioned in unattached kinetochores to act on SAC proteins recruited to the kinetochore by Mps1 activity<sup>37</sup> (Figure 2A). Therefore, it may also phosphorylate Spc105/KNL1, Bub1, or Mad1 and thus promote MCC formation. To test this hypothesis, we conditionally dimerized Ipl1 with either a fragment of Spc105 spanning its six ‘MELT’ motifs, Bub1, or Mad1. Rapamycin-induced dimerization of Ipl1 with the Spc105 fragment did not affect the cell cycle, but its dimerization with either Bub1 or Mad1 induced a G2/M arrest (Figure 2B). The morphology of these cells was consistent with a metaphase-arrest: large buds and an intact spindle with two bioriented kinetochore clusters (Figure 2B). Ipl1-Bub1 dimerization did not affect cell cycle progression in *mad1* mutants (Figure 2B blue curve in the middle panel). Thus, the arrest required a functional SAC.

To ensure that Ipl1-Bub1 dimerization did not affect kinetochore biorientation, we created a strain expressing Ipl1 and Ipl1-FRB both. Chromosome IV bioriented efficiently in both control and rapamycin-treated cells of this strain (Figure 2C top, Figure S2A). A kinase-dead allele of Ipl1, Ipl1<sup>K133R</sup>, did not cause the G2/M arrest when dimerized with Bub1 indicating that the kinase activity of Ipl1 is required for eSAC signaling<sup>38</sup> (Figure 2C top). Finally, to confirm that the mitotic arrest resulting from Ipl1-Bub1 dimerization is independent of kinetochores, we used a fragment of Bub1, bub1<sup>368–609</sup>, comprising just the central domain, lacking the Bub3-binding ‘GLEBS’ domain and the kinase domain<sup>39</sup>. GFP-bub1<sup>368–609</sup>-2xFkbp12 did not localize to unattached kinetochore clusters in nocodazole-treated cells (Figure 2C bottom). Importantly, Ipl1 dimerization with GFP-bub1<sup>368–609</sup>-2xFkbp12 robustly activated the SAC.

To find sites within the Bub1 central domain phosphorylated upon its dimerization with Ipl1, we affinity purified GFP-bub1<sup>368–609</sup>-2xFkbp12 from rapamycin- and DMSO-treated cells (Figure S2B). In SDS-PAGE analysis, the mobility of GFP-bub1<sup>368–609</sup>-2xFkbp12 affinity-purified from rapamycin-treated cells was retarded, suggesting that it was post-translationally modified (Figure S2B). Mass spectrometry identified T438, S474, S475, T550, T556, and S596 in the Bub1 central domain as phosphorylated (Table S2). Importantly, these phosphorylations were significantly enriched in rapamycin-treated cells. Although our analysis identified only one of the 15 sites implicated in Bub1-Mad1 interaction, it suggests that following its rapamycin-induced dimerization, Ipl1 phosphorylates Bub1, and potentially Mad1, to drive eSAC signaling.

### Intact ABBA motif in Bub1 is essential for the Aurora B/Ipl1-mediated ectopic SAC activation

We next examined the residues in Bub1 needed for eSAC activity. Ipl1 dimerization with bub1<sup>T453A, T455A</sup> did not affect cell cycle progression (Figure 2D top). Ipl1 dimerization with bub1<sup>T453A</sup> (predicted to be a Cdk1 phospho-site) arrested the cell cycle, implicating Bub1(455T) as a residue critical for Ipl1-driven eSAC signaling (Figure S2C left).

Bub1(485T) was also similarly found to be critical (Figure 2D top, Figure S2C and S2D). Since Ipl1 and Mps1 can both phosphorylate Bub1, we wanted to know if Mps1 becomes non-essential when Ipl1 is dimerized with Bub1. Ipl1-driven eSAC signaling was abolished when the kinase activity of an analog-sensitive Mps1 allele was conditionally inhibited<sup>40</sup> (Figure S2E). Thus, Mps1 must prime Bub1 for Ipl1 activity.

We next tested whether the Bub1 ABBA motif is essential for Ipl1-driven eSAC signaling. Surprisingly, Ipl1 dimerization with *bub1*<sup>-abba</sup> did not affect the cell cycle (Figure 2D bottom flow cytometry panel). Mps1-driven eSAC activity is unaffected by the same mutation (Figure 1C). Thus, only Ipl1-driven eSAC signaling requires the Bub1 ABBA motif to be intact. Consistently, Ipl1 dimerization with Mad1 in either cells lacking Bub1 or in cells that express either *bub1*<sup>-abba</sup> or *bub1*<sup>T485A, T509A, T518A</sup> did not affect the cell cycle (Figure 2E).

These data advance the following model for the direct role of Ipl1 in MCC production. Mps1 activates the SAC by sequentially phosphorylating the MELT, Bub1, and Mad1 to license the recruitment of Bub1-Bub3, Mad1-Mad2, and Cdc20, respectively. Although Ipl1 localizes to unattached kinetochores, it cannot activate the SAC on its own because it cannot phosphorylate the MELT motifs<sup>13,14</sup>. After Mps1 phosphorylates the MELT motifs and Bub1, Ipl1 phosphorylates Bub1 to further promote Mad1-Mad2 recruitment. Finally, Ipl1 cannot phosphorylate Mad1 to enable the Mad1-Cdc20 interaction; Mad1 must cooperate with Bub1 to promote MCC formation<sup>32,33</sup>.

At this juncture, it is important to note two properties of the eSAC system that likely accentuate its signaling activity. First, by labelling the genomic copy of Ipl1 with Frb, nearly all Ipl1 in a cell will dimerize with the Fkbp12-tagged SAC protein (depending on its relative abundance). Second, the high affinity of rapamycin-mediated dimerization of Fkbp12 and Frb will allow Ipl1 to maximally phosphorylate the signaling protein. Under physiological conditions, this Ipl1 contribution is likely to be significantly smaller<sup>41</sup>.

### **Evidence supporting a direct role of Aurora B/Ipl1 in driving MCC assembly in kinetochore-based SAC signaling**

To detect the contribution of Ipl1 to kinetochore-based SAC signaling, two conditions must prevail. First, Mps1 activity in the kinetochore must be minimal so that the Ipl1 contribution can be detected. Second, Bub1 must still be recruited to the kinetochore so that Ipl1 can act on it. As an appropriate model for these conditions, we used *spc105*<sup>RASA</sup>, a well-characterized mutant of Spc105. In this mutant, the highly conserved 'RVSF' motif that binds Protein Phosphatase 1 (PP1) is inactivated. Consequently, the MELT motifs remain phosphorylated, and Bub3-Bub1 remains bound to the MELT motifs in bioriented kinetochores<sup>14</sup>. Thus, the SAC remains active even after kinetochore biorientation<sup>30,42,43</sup>. The concurrence of persistent Bub1 recruitment to stably attached kinetochores with diminished Mps1 activity provides the requisite conditions for observing Ipl1 contributions to SAC signaling. Indeed, the study by Rosenberg et al. found that a hypomorphic, temperature-sensitive mutant of Ipl1 suppresses the SAC-mediated lethality of *spc105*<sup>RASA</sup>.

The Bub1 ABBA motif is necessary for Ipl1 mediated, but not for Mps1-mediated, SAC signaling. Therefore, we studied genetic interactions between *bub1<sup>-abba</sup>* and *spc105<sup>RASA</sup>*. We found that *bub1<sup>-abba</sup>* mutation rescued the viability of *spc105<sup>RASA</sup>* (Figure 2F, left). We observed a similar rescue of *spc105<sup>RASA</sup>* by *bub1<sup>T455A, T485A</sup>* and *bub1<sup>T485A, T509A, T518A</sup>* (Figure S2F and *bub1<sup>T453A, T455A</sup>*, also see reference<sup>30</sup>). Importantly, the *bub1<sup>-abba</sup> spc105<sup>RASA</sup>* mutant had a functional checkpoint (Figure 2E, bottom). These genetic interactions imply that the Bub1-mediated recruitment of both Mad1 and Cdc20 is necessary for persistent SAC signaling from bioriented kinetochores in the *spc105<sup>RASA</sup>* mutant. Together with the requirement of Ipl1 kinase activity for SAC signaling in the *spc105<sup>RASA</sup>* mutant, these data support our hypothesis that Ipl1 directly promotes MCC formation from unattached kinetochores.

Ipl1 may phosphoregulate the Cdc20 recruited by Bub1 to promote SAC signaling. We ruled out this possibility by studying genetic interactions between *spc105<sup>RASA</sup>* and several Cdc20 mutants wherein the known or predicted phosphorylation sites in Cdc20 are non-phosphorylatable (data now shown).

### Aurora B drives ectopic SAC signaling in human cells

In human cells, Aurora B promotes SAC signaling indirectly by: (1) creating unattached kinetochores, (2) potentiating Mps1 recruitment to the kinetochore<sup>10</sup>, and (3) inhibiting the phosphatase activity antagonizing Mps1<sup>9</sup>. However, in fission yeast, Aurora B activity is necessary for maintaining mitotic arrest induced by unattached kinetochores<sup>21</sup>. Thus, the creation of unattached kinetochores is not its only role in SAC signaling. The requirement of Aurora B kinase activity for maximal SAC signaling has also been noted<sup>20</sup>. In human and fission yeast cells, Aurora B kinase activity and Bub1 are both required for SAC signaling driven by Mad1 that is artificially tethering to bioriented kinetochores<sup>44–47</sup>, similar to the requirement of Bub1 when Aurora B and Mad1 are dimerized in yeast cells (Figure 2D).

To test if Aurora B can drive eSAC signaling in HeLa cells, we adapted the previously described eSAC system<sup>13</sup>. We created cell lines that constitutively express mNeonGreen-2xFkbp12 fusion of either a KNL1 (Spc105 homolog) phosphodomain containing six MELT motifs (two tandem copies of a fragment spanning three motifs in KNL1<sup>48</sup>), the central domain of Bub1, or the C-terminal domain of Mad1 (Figure 3A, Methods). In these cells, we conditionally expressed Frb-mCherry-INCENP<sup>818–918</sup>. INCENP<sup>818–918</sup> binds to and activates Aurora B in human cells<sup>49</sup>. As expected, the INCENP fragment was cytosolic, and did not show detectable localization at kinetochores (Figure S3A). We used the cell-to-cell variation in Frb-mCherry-INCENP<sup>818–918</sup> expression to characterize the dependence of mitotic duration on the eSAC dosage<sup>13</sup> (Figure 3A–B).

Rapamycin-induced dimerization of Frb-mCherry-INCENP<sup>818–918</sup> with mNeonGreen-2xFkbp12 did not affect the duration of mitosis (Figure 3D), indicating that INCENP<sup>818–918</sup> over-expression does not affect mitotic duration. INCENP<sup>818–918</sup> dimerization with the KNL1 fragment containing six MELT motifs also did not affect mitotic progression (Figure 3B, left, Video S1 left panel). Consistently, western blot analysis of whole cell lysates following rapamycin treatment showed that the ‘MEIT’ motifs (variants of the consensus ‘MELT’ sequence) in the eSAC phosphodomain were

not phosphorylated (Figure 3C, Figure S3B–C). INCENP<sup>818–918</sup> dimerization with either Bub1<sup>231–620</sup> or Mad1<sup>479–725</sup> resulted in a dose-dependent mitotic delay (Figure 3B, middle and right, Videos S1 middle and right panels). The maximal delay in both cases was similar in magnitude, and comparable to the maximal delay caused by the dimerization of the Mps1 kinase domain with the same protein fragments (Figure 3D; data marked with an asterisk are reproduced from<sup>13</sup> for comparison). Thus, Aurora B also drives eSAC signaling by phosphorylating either Bub1 or Mad1, or both.

Aurora B-driven eSAC activity persisted even when it was dimerized with a fragment of Bub1, Bub1<sup>271–620</sup>, lacking the Bub3-binding GLEBS motif and the N-terminal TPR domain<sup>39,50</sup>. Thus, the eSAC activity is kinetochore-independent (Figure 3E, also see Figure S3A). The same was true for Mps1-driven eSAC activity (Figure 3E left). In fact, the maximal delay was slightly higher and therefore the eSAC activity stronger, presumably because Bub1<sup>271–620</sup> does not sequester Bub3, thus ensuring the full availability of Bub3-BubR1 for MCC formation<sup>51</sup>. eSAC activity also requires an active Aurora B kinase because direct dimerization of the kinase domain of Aurora B (residues 61–344), with the Bub1 phosphodomain did not affect the mitotic progression (Video S2).

Finally, we tested whether the observed mitotic delays are due to ectopic MCC formation. We synchronized HeLa cells expressing INCENP<sup>818–918</sup> and Bub1<sup>231–620</sup> in G2/M and then released them into media either with or without rapamycin. In each case, we harvested mitotic cells, prepared clarified cell lysates, and immunoprecipitated Cdc20. We performed the same assay for cells wherein Mps1 kinase domain is dimerized with Bub1<sup>271–620</sup>-mNeonGreen-2xFkbp12. In both cases, increased amounts of Mad2 co-immunoprecipitated with Cdc20 from rapamycin-treated cells compared to DMSO-treated cells (Figure S3D). Thus, INCENP<sup>818–918</sup> dimerization with Bub1<sup>271–620</sup> enhances Cdc20:C-Mad2 levels. The increase in Mad2 was greater in the Mps1-driven eSAC system than in the Aurora B driven system likely because Aurora B works downstream from Mps1.

### **The ABBA motif of human Bub1 is necessary for the ectopic SAC activation by Aurora B**

We next dimerized Bub1<sup>271–522</sup>, which lacks the ABBA motif, with either the Mps1 kinase domain or INCENP<sup>818–918</sup>. Mps1-driven eSAC activity persisted in this case, but Aurora B-driven eSAC activity was significantly weaker (Figures 3E–F). These results mirror our findings from budding yeast: Bub1 ABBA motif is dispensable for Mps1-driven eSAC activity, but necessary for Aurora B-driven eSAC activity. This observation also implies that the mitotic delay observed upon Frb-mCherry-INCENP<sup>818–918</sup> dimerization with Mad1<sup>479–725</sup> will require the Bub1-Mad1 interaction, which in turn requires Mps1 activity. Rapamycin-induced dimerization of INCENP<sup>818–918</sup> and Mad1<sup>479–725</sup> failed to delay cell division in cells treated with the Mps1-inhibitor Reversine (Figure S3E). Thus, Mps1 kinase activity is still required for the eSAC activity induced upon INCENP<sup>818–918</sup> dimerization with Mad1<sup>479–725</sup>.

### **Aurora B kinase activity promotes MCC assembly during kinetochore-based SAC signaling**

To detect the contribution of Aurora B to kinetochore-based SAC signaling in HeLa cells, an additional condition must be fulfilled apart from the two mentioned earlier. Aurora B

downregulates PP1 and PP2A activity unattached kinetochores, which both antagonize SAC signaling. To negate these SAC antagonists, it becomes necessary to inhibit their activity<sup>9</sup> following Aurora B inhibition. To enable this, we used the following approach. We released G1/S synchronized HeLa cells expressing H2B-RFP into the cell cycle and treated them with nocodazole to activate the SAC. In these cells, we partially suppressed Mps1 kinase activity to license Bub1-Bub3 recruitment in the unattached kinetochores<sup>48</sup>. We suppressed PP2A recruitment to the kinetochore either by RNAi mediated knockdown of the five B56 isoforms that target PP2A to the kinetochore or by using Calyculin A<sup>52</sup>.

As in prior studies, partial inhibition of Mps1 significantly reduced the average duration of the mitotic arrests to  $126 \pm 100$  minutes (mean  $\pm$  S.D., Figure 4A, compared to  $> 1000$  minutes in cells treated with nocodazole alone, data not shown). B56 RNAi increased the duration of the mitotic arrest to  $258 \pm 160$  minutes<sup>9</sup> (mean  $\pm$  S.D., Video S3 left). When Aurora B activity was inhibited using the small molecule inhibitor ZM447439 under the same condition, the mitotic arrest was completely abolished ( $15 \pm 6$  minutes, Video S3 right). Calyculin A-treated cells similarly exited mitosis soon after entering it (Figure 4A). These experiments suggest that Aurora B kinase activity contributes to SAC signaling directly and independently from its indirect role in retarding SAC silencing.

In summary, our data reveal that Aurora B can phosphorylate Bub1 to promote its interaction with Mad1, and thus contribute directly to MCC formation (Figure 4B). Aurora B does not activate the SAC on its own, because it cannot phosphorylate the MELT motifs in Spc105/KNL1. After Mps1 phosphorylates the MELT motifs and Bub1<sup>5,6</sup>, Aurora B can act on Bub1 to promote the Mad1-Mad2 recruitment. This coordinates the interaction between Mad1-Mad2 and the Cdc20 molecule recruited by the ABBA motif in Bub1, facilitates the formation of the closed-Mad2-Cdc20 complex and, ultimately, the MCC<sup>32,33</sup>. The requirement of Mps1 upstream from Aurora B in kinetochore-based SAC signaling and the significant overlap among the phosphorylation targets of the two kinases prevented us from testing this model directly. Nonetheless, it explains prior observations showing that Aurora B cooperates specifically with Bub1 in SAC signaling<sup>18</sup>.

Aurora B's role in promoting MCC formation will be physiologically significant, especially when Mps1 activity in the kinetochore is weakened. One such situation occurs in kinetochores with end-on, but syntelic, attachments (Figure 4C). End-on attachments suppress Mps1 activity<sup>53-56</sup> and weaken Mad1 recruitment via the SAC signaling cascade and possibly through the fibrous corona<sup>57</sup>. In these kinetochores, Aurora B can promote MCC formation, delay anaphase onset, and thereby reduce chromosome missegregation. Indeed, Aurora B and the ABBA motif in Bub1 are both essential for SAC signaling in Taxol-treated cells, wherein kinetochores maintain end-on attachments<sup>17,18</sup>. The direct role of Aurora B in SAC signaling may also contribute to the positive correlation between centromeric tension and SAC signaling.



## STAR Methods

### Resource Availability

**Lead Contact**—Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Ajit P. Joglekar (ajitj@umich.edu).

**Materials Availability**—Yeast strains, HeLa cell lines, and plasmids constructed in this study are available from the lead contact upon request.

### Data and Code Availability

- Original western blot images are displayed in Data S1. Microscopy data reported in this paper will be shared by the lead contact upon request.
- This study does not report any original code.
- Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

### Experimental Model and Subject Details

**Yeast Cell culture**—Yeast strains were grown in YPD (yeast extract 1%, peptone 2%, dextrose 2%) or synthetic media supplemented with 2% dextrose (as per requirement of the yeast strain) at 32°C. At the time of imaging strains with TetR-GFP and *CENIV-TetO*, we supplemented the growth media with uracil (final 40µg/ml) to distinctively observe TetR-GFP bound to *CENIV-TetO* array.

To induce meiosis or sporulation, diploid yeast strains were grown in YPD overnight to stationary phase. Next day, the cells were pelleted and resuspended them with starvation media (0.1% yeast extract, 1% potassium acetate, 0.025% dextrose) and incubated 4–5 days at RT. To obtain the strain of interest, plates with dissected tetrads were incubated for 2–3 days. Segregants with wild-type genotype or those harboring *spc105*, *spc105<sup>RASA</sup>*, *bub1<sup>-abba/phosphomutants</sup>* grew within that time period. Infrequently, segregants with *spc105*, *spc105<sup>RASA</sup>* form micro colonies after 5–6 days of incubation at 30C (Figure 2F, left). To ensure that background mutations are not responsible for the rescue of *spc105<sup>RASA</sup>* in *bub1<sup>-abba</sup>* background, mutant segregants were back-crossed wild-type parent strains (YEF473).

For the experiment involving analog sensitive Mps1 yeast cultures were grown for 3h till they attained mid-log phase. These cultures were treated with Hydroxyurea (100mM final) for 2h 30min to synchronize the cells late S phase. Following that, the cells were washed with YPD and released into either YPD (control) or YPD supplemented with 1-NMPP1 (50µM final). After 15min of incubation with 1-NMPP1, either DMSO (control) or rapamycin (1 µg/ml; to mediate the dimerization of Aurora B/Ipl1-Frb-GFP and Bub1–2xFkbp12) was added to the media. Mitotic cells were categorized as prometaphase, metaphase and anaphase cells according to the distribution of fluorescently labeled kinetochores within each cell (representative images in Figure S2E). The unbudded cells

were considered as the cells in G1 and thus they were not taken into consideration in our analyses.

**Tissue culture and generation of stable cell lines**—Henrietta Lacks (HeLa) cells were grown in DMEM media with 10% FBS, 1% Pen/Strep, and 25 mM HEPES at 37 °C and 5% CO<sub>2</sub>. Stable cell lines expressing the two eSAC components were generated by integrating a bi-cistronic eSAC plasmid at an engineered *Loxp* site in the HeLa genome according to the protocol described in <sup>62</sup>. Clones with stable integration of the eSAC plasmid were selected using Puromycin (1 ug/ml), and several clones were pooled together to create the cell cultures used in the experiments.

To conduct dose-response analysis, each eSAC cell line was plated ~ 40–48 hours prior to the start of the experiment in DMEM media without Puromycin. Doxycycline was added at the time of plating to induce the expression of either Frb-mCherry-Mps1 or Frb-mCherry-INCENP<sup>818–918</sup>. Prior to imaging, the cells were washed with PBS. Fluorobrite media with 10% FBS, 1% Pen/Strep with or without Rapamycin were added to each well.

## Method Details

**Plasmid and strain construction for study involving *S. cerevisiae***—Plasmids and *S. cerevisiae* strains and cell lines used in this study are tabulated in Table S3. *S. cerevisiae* strains containing multiple genetic modifications were constructed using standard yeast genetics. Proteins tagged with GFP(S65T) and mCherry or yeast codon optimized mCherry were used to visualize kinetochores, spindle pole bodies and SAC signaling components. A 7-amino-acid peptide (sequence: ‘RIPGLIN’) was used as the linker between the proteins and their C-terminal tags (GFP, mCherry, Frb or 2xFkbp12). The cassettes for gene deletion, gene replacement and C-terminal tags were introduced at the endogenous locus through homologous recombination of PCR amplicons or using linearized plasmids <sup>59</sup>. In the past, significant strain to strain variation in the intensity of mCherry-tagged kinetochore proteins or checkpoint proteins was observed. This variation arises from the inherent variability of mCherry brightness. Therefore, all Mad1-mCherry strains were created by crossing the same transformant of Mad1-mCherry (AJY1836 or AJY3741) with other strains. The deletion mutant of *NUP60* always accompanies Mad1-mCherry to disrupt Mad1 localization to the nuclear envelopes <sup>60</sup>. This facilitated clearer imaging and quantification of Mad1 localized to the unattached kinetochores without affecting SAC strength.

To create any diploid yeast strains, overnight cultures of a and  $\alpha$  mating types were mixed and spotted on a YPD plate, and then incubated for approximately 3–4 hours at 32°C.

All the Spc105 mutants used in the study are chimeras of Spc105 and GFP as described previously<sup>30,43</sup>. Genes encoding the chimeric proteins were introduced using a cassette that consists of the 397 bp upstream and 250 bp downstream sequences of the *SPC105* open reading frame as promoter (*prSPC105*) and terminator (*trSPC105*) sequences respectively. Genes encoding GFP(S65T) at the 222<sup>nd</sup> or 455<sup>th</sup> amino acid positions of Spc105 were introduced by sub-cloning with an extra *Bam*HI site (Gly-Ser) upstream and *Nhe*I site (Ala-Ser) downstream from GFP. The plasmids based on pRS305 or pRS306 backbone were

linearized by *Bst*ÆII or *Stu*I before transformations to ensure their integration at the *LEU2* or the *URA3* locus respectively.

To build *bub1* phosphomutants containing plasmids the pSK954 plasmid backbone was used<sup>61</sup>. pSK954 harbors the *ADH1* transcription terminator cloned within *Asc*I-*Bgl*II sites. 500bp sequence upstream of the *BUB1* start codon, 3.063kb *BUB1* ORF sequence harboring the designated mutations and 651bp *2xFKBP12* or 705bp yeast mCherry were subcloned using *Sac*II-*Asc*I sites. The ORF and *2xFKBP12* or mCherry were linked by 21bp linker which codes for RIPGILK. 350bp sequence downstream of the *BUB1* stop codon was subcloned between *Pme*I-*Apa*I to serve as the terminator. To build the strains with *bub1* phosphomutant allele, a strain hemizygous for BUB1 was used (AJY6055). The plasmids were digested by *Apa*I and *Sac*I to release 6.279kb fragment which recombined at the deleted *bub1* locus replacing the *NAT1* cassette. There are two chimeras that express *bub1*<sup>T453A, T455A</sup> (pAJ852 and pAJ896). *BUB1* ORF of pAJ852 harbors mutations of 449SR450::TG. However, upon testing no phenotypic differences were detected between the strains constructed by pAJ852 and pAJ896. Contrary to Mad1-mCherry strains, *bub1*-15A-mCherry strains were created via gene replacement using linear fragments (linearized with *Apa*I-*Sac*I) of pAJ923. Therefore, the difference in intensities between wild-type and *bub1*-15A observed in figure S1E may have been caused by differences in mCherry brightness rather than protein localization.

pSB148 which contains *IPL1* ORF flanked 1.0 Kb promoter (*prIPL1*) and 654 bp terminator (*trIPL1*) was acquired from the Biggins lab. FRB-GFP along with ADH1 terminator was first cloned within *Age*I-*Sac*I sites to generate a chimera which can express Ipl1-Frb-GFP (pAJ941). Then a 600 bp fragment, which was synthesized by Integrated DNA technologies and harbors kinase dead mutation of Ipl1 (K133R), was cloned within the *Swa*I-*Age*I sites to build pAJ940. AJY6156 (*fpr1*, *BUB1*-1x*FKBP12*-*HIS3*, *DSN1*-mCherry-*HYG*) was transformed with *Stu*I digests of these plasmids where they can be integrated in *URA3* loci.

Similarly, to construct the mutants of putative phosphorylation sites of Cdc20, 506bp sequence upstream of the *CDC20* start codon and 1.833kb *CDC20* ORF sequence harboring the designated mutations were cloned into the *Sac*II-*Asc*I sites of pSK954. A *Spe*I site (ACTAGT) was inserted between the promoter and the ORF sequence. Finally, 300bp sequence downstream of the *CDC20* stop codon was cloned between *Pme*I-*Kpn*I sites. To build strains with *cdc20* phosphomutant alleles, a strain hemizygous for *CDC20* was used (AJY5249). The plasmids were digested by *Kpn*I and *Sac*II to release 4.328kb fragment which recombined at the *CDC20* locus replacing the *TRP1* cassette.

**Plasmid and cell line construction for study involving HeLa cells**—The plasmids used for the stable cell lines were based on the plasmids that have been described previously<sup>13</sup>. Briefly, the phosphodomain was integrated into the constitutively expressed ORF of the plasmid using either *Not*I or *Asc*I and *Xho*I restriction sites. The INCENP<sup>818-918</sup> fragment was integrated into the conditionally expressed ORF using *Fse*I and *Bgl*II restriction sites.

**Flow cytometry**—To perform these experiments, the designated strains were grown to mid log phase. Media were then supplemented with Nocodazole (final concentration 15µg/ml)

to depolymerize the spindle microtubules and activate the SAC and rapamycin (1  $\mu\text{g}/\text{ml}$ ) to induce the dimerization of FRB and Fkbp12 fused proteins<sup>63</sup>. Samples containing approximately 0.1 OD<sub>600</sub> cells were collected 0, 1, 2, 3 and 4h after nocodazole addition, and the cells were fixed using 75% ethanol, and stored at 4°C overnight. Next day, the cells washed and treated the cells with bovine pancreatic RNase (Millipore Sigma, final concentration 170ng/ $\mu\text{l}$ ) at 37°C for 24h in RNase buffer (10mM Tris pH8.0, 15mM NaCl). Next, RNase was washed out and the cells resuspended in 1X phosphate buffered saline (pH 7.4) and stored at 4°C. These samples were incubated in Propidium Iodide (Millipore Sigma, final concentration 5 $\mu\text{g}/\text{ml}$  in PBS) for at least 1h at RT on the day of the assay. The stained cells were analyzed using the LSR Fortessa (BD Biosciences) in Biomedical research core facility, University of Michigan medical school. For each strain flow cytometry was performed at least twice. Representative results from one of these experiments are displayed in each panel. The data was analyzed using the FlowJO software and the graphs were adjusted by Adobe illustrator. As positive controls for SAC null phenotype, *bub1* or *mad2* strain were used.

**Microscopy for *S. cerevisiae* cells and image analysis**—A Nikon Ti-E inverted microscope with a 1.4 NA, 100X, oil-immersion objective was used for all imaging experiments. Additionally, the 1.5X opto-var lens was used to measure Mad1-mCherry intensities. The cells were imaged at room temperature in synthetic dextrose (or synthetic galactose media whenever it was required for the assay) supplemented with essential amino acids to obtain at least 20 microscopic fields at a given time points for any strains. Mounting media were supplemented with nocodazole to image the nocodazole arrested cells. For each field of view, a ten-plane Z-stack was acquired (200nm separation between adjacent planes), and at least 20 fields were acquired in each experiment.

Total fluorescence intensities of kinetochore clusters (16 kinetochores in metaphase) were measured by integrating the intensities over a 6 $\times$ 6 region centered on the maximum intensity pixel. Median intensity of pixels immediately surrounding or a nearby 6 $\times$ 6 area was used to correct for background fluorescence. Fluorescence intensity was calculated as described previously<sup>64,65</sup>.

**Drug treatments and RNAi for experiments with human cells**—To induce the expression of either mCherry-Frb-Mps1 kinase domain or -Incenp<sup>818–918</sup>, doxycycline was added to a final concentration of 2  $\mu\text{g}/\text{ml}$  (stock concentration 2 mg/ml in DMSO). To induce the dimerization of protein fragments, Rapamycin was added ~ 1 hour prior to the start of the experiment to a final concentration of 500 nM (stock concentration 500  $\mu\text{M}$  in DMSO). GSK-923295 was added to the final concentration of 15 nM (stock concentration 236  $\mu\text{M}$ ). Partial Mps1 inhibition was achieved by adding Reversine to the final concentration of 250 nM (stock concentration 500  $\mu\text{M}$  in DMSO). Nocodazole was added to the final concentration of 330 nM (stock concentration 330  $\mu\text{M}$  in DMSO). ZM447439 was added to the final concentration of 10  $\mu\text{M}$  (stock concentration 3mM in DMSO). Calyculin A was added to the final concentration of 100nM (stock concentration 50 $\mu\text{M}$  in DMSO). The cocktail of siRNA against five different B56 isoforms was added to

a final concentration of 40 nM (stock concentration 10  $\mu$ M). The siRNA sequences were obtained from ref. <sup>9</sup>.

**Long term live Cell Imaging of HeLa cells and Image analysis**—Imaging was conducted over a period of 24 hours as described in detail previously <sup>13</sup>. Either the Incucyte Zoom Live Cell Imaging system (Sartorius Inc.) or the ImageExpress Nano live cell imaging system (Molecular Devices) using 20x Phase objectives for imaging. To image cells on the Incucyte system, cells were plated in 12-well plastic tissue culture plates, whereas they were plated in 24-well plate glass-bottom dishes for imaging using the ImageExpress Nano system. Typically, 4 positions were selected within each well for imaging. At each position, one phase, GFP, and mCherry image was acquired every 10 minutes. The exposure time for mCherry image was adjusted to minimize photobleaching while ensuring accurate determination of cellular intensity values. It should be noted that the excitation intensity of the Incucyte instrument declined significantly over the course of this study. Furthermore, a small minority of the experiments were carried out on the ImageExpress Nano microscope, which has excitation sources, optics, and detector that are entirely different from the components of the Incucyte microscope. Therefore, the mCherry intensity values across different experiments are not directly comparable. The duration of mitosis and GFP and mCherry fluorescence per cell were determined using a custom image analysis script implemented by a Matlab graphical user interface as described previously <sup>13</sup>.

**Immunofluorescence assay in HeLa cells**—Immunofluorescence assay was performed as described previously (Deluca et al., 2011, J Cell Sci). We plated cells expressing Frb-mCherry-INCENP<sup>818–918</sup> on a 12mm coverslip until they reached 80% confluence. The cells were treated with 15 nM GSK-923295 for 3 h to activate SAC. During fixation, the cells were pre-extracted with 0.5% Triton X-100 in 0.1 M PHEM (240 mM Pipes, 100 mM HEPES, 8 mM MgCl<sub>2</sub> and 40 mM EGTA) and fixed with 4% PFA for 10 minutes. The coverslips were washed three times with 0.1 M PHEM and blocked for 30 min at room-temperature with StartingBlock (Thermo scientific, 37578). Next, the cover slips were incubated in primary antibody (Mouse anti-Hec1, 1:3000) over night at 4° C. Next day, the coverslips were washed 4 times with 1xPHEM containing 0.05% Tween-20 and incubated with secondary antibodies (Goat anti-Mouse 488, 1: 10000) for an additional 45 min at room temperature in dark. Following that, the coverslips washed again four times and mounted in antifade (ProLong; Molecular Probes).

Immunofluorescence images were taken on a Nikon inverted microscope equipped with a Crest X-Light V2 LFOV25 Spinning Disk Confocal head, and Photometric 95B Prime CMOS camera. For each field of view, 31 Z sections were acquired at 0.2 mm steps using a 100 $\times$  3, 1.4 Numerical Aperture (NA) Nikon objective.

**Immunoprecipitation of Cdc20**—This assay was performed as described in <sup>66</sup>. Cells expressing Bub1<sup>271–620</sup>-neon2xFkbp12, Frb-mCherry-Mps1 or Bub1<sup>225–620</sup>-mNeon-2xFkbp12, Frb-mCherry-Incenp<sup>818–918</sup> were grown to ~ 50% confluence. These cells were synchronized in S phase using double thymidine treatment (final concentration 2.5 mM). At the same time, doxycycline (final concentration 2  $\mu$ g/ml) was added to the media to induce expression of Frb-mCherry-Mps1 kinase domain or Frb-mCherry-

INCENP<sup>818–918</sup>. G1/S synchronized cells were washed with PBS and released into media supplemented with the Cdk1 inhibitor RO-3306 (final concentration 15 nM). After 20 hours, G2-synchronized cells were washed with PBS and released into media supplemented with rapamycin (1 µg/ml) for 4 h.

Mitotic cells were harvested using plate shake-off followed by centrifugation at room temperature/ 1100 rpm/ 5 min. Cells were treated with a volume of lysis buffer (75 mM HEPES, pH 7.5; 150 mM KCl, 1.5 mM MgCl<sub>2</sub>, 1.5 mM EGTA, 10% glycerol, 1% CHAPS, supplemented with protease inhibitor and phosphatase inhibitor cocktails) added in proportion to the weight of the cell pellet. After a 10 min incubation on ice, total cell lysates were clarified by centrifugation (4°C/ 13,000 rpm for 10 min). The cell lysates were incubated with α-Cdc20 antibody-conjugated protein G-Sepharose 4B beads (4 µg antibodies per 10 µl of beads, Thermo Scientific, catalog #20399) at room temperature for at least 1 h. After that, the beads were washed three times with lysis buffer and boiled in Laemmli sample buffer.

**Affinity purification of Bub1 middle domain and mass spectrometry**—Mid-log phase cells expressing Ipl1-Frb and GFP-Bub1<sup>368–609</sup>-2xFkbp12 were treated with either DMSO (control) or Rapamycin for approximately 3 h. GFP-Bub1<sup>368–609</sup>-2xFkbp12 was immunoprecipitated from clarified cell lysates using GFP-TRAP beads following the methodology described previously<sup>43,67</sup>. Precipitated proteins were eluted into Laemmli sample buffer and subjected to SDS-PAGE analysis (See Figure S2B). Incisions ~0.5cm tall were made in the Coomassie stained SDS-PAGE, and bands were further processed for tandem mass spectrometry at the University of Michigan proteomics resource facility (See Figure S2B). Mass spectrometry data was filtered to retain peptides/peptide spectrum matches (PSM) with false discovery rate (FDR) <1%. The detected sites and flanking sequences are included in the table S2. The fold change from DMSO to rapamycin was calculated using normalized peptide abundance.

**Immunoblotting**—Western blotting was performed using commercial antibodies. The specifications of antibodies and their dilutions are as follows: Mouse α-GFP, 1: 3,000; mouse α-Ds-Red, 1: 2,000; mouse α-βTubulin, 1: 15,000; rabbit α-Fkbp12, 1: 5,000; rabbit α-PhosphoMELT (MEIpT, MELT13/17), 1: 2000; mouse α-Cdc20, 1:500; mouse α-Mad2, 1:1000; mouse α-BubR1, 1:1000; mouse α-Apc3, 1:1000. The primary antibodies were detected using HRP conjugated secondary antibodies (1: 10,000) per the manufacturer's instructions. The subsequent chemiluminescence was detected using the C600 imager from Azure Biosystems. The band intensities were measured by ImageJ<sup>68</sup>.

**Molecular weights of the target proteins**—Molecular weights of the proteins targeted in the immunoblots and Coomassie stained gels in this study, obtained from Saccharomyces Genome Database and Uniprot: yeast α-Tubulin-49.8 kDa, yeast GFP-Mad1- 115.2 kDa, yeast GFP-Mad3- 87 kDa, yeast GFP-bub1<sup>368–609</sup>-2xFkbp12- 79.2 kDa, human Frb-mCherry-INCENP<sup>818–918</sup>- 50 kDa, human β-Tubulin- 50 kDa, M6-mNeonGreen-2xFkbp12- 101.0 kDa, human Mps1 (Kinase)-Frb-mCherry- 80.0 kDa, human Mad2- 23.5 kDa, human Cdc20- 54.7 kDa, human BubR1- 119.54 kDa, human Apc3- 91.86 kDa.

## Quantification and Statistical Analysis

The technical replicates represent the number of times each experiment was performed. The biological replicates are defined as multiple transformants or segregants of the same strain which contain identical genotype. For imaging experiments, the number of cells analyzed for each strain and number of experimental replications is noted in the figure legends. All statistical analysis was performed using GraphPad Prism (version 8). The data were normalized with the mean intensities obtained for wild-type controls in each experiment to prepare the scatter plots of Mad1 intensities. To compare sample means in all other cases, either the t-test or two-way ANOVA test was applied to ascertain the statistical significance of the rest of the data using GraphPad Prism (version 8). The p-values obtained from these tests are indicated in the figures.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgements

This work was funded by the 5R35-GM126983 from NIGMS to APJ. We thank Prof. Mara Duncan and her lab (Department of Cell and Developmental Biology, University of Michigan Medical School) for their help. We acknowledge all the Joglekar lab members for their constructive criticism. We specially thank our past lab member Alan A. Goldfarb, who did the initial pilot assay to show that rapamycin induced dimerization of Mps1-FRB with Mad1-Fkbp12 arrests the cell cycle. The authors acknowledge that this work would not have been possible without the HeLa cell line, which was developed from Henrietta Lacks' cells taken without compensation or informed consent.

## References

1. Musacchio A (2015). The Molecular Biology of Spindle Assembly Checkpoint Signaling Dynamics. *Curr Biol* 25, R1002–1018. [PubMed: 26485365]
2. Lampson MA, and Cheeseman IM (2011). Sensing centromere tension: Aurora B and the regulation of kinetochore function. *Trends Cell Biol* 21, 133–140. [PubMed: 21106376]
3. London N, and Biggins S (2014). Mad1 kinetochore recruitment by Mps1-mediated phosphorylation of Bub1 signals the spindle checkpoint. *Genes Dev* 28, 140–152. [PubMed: 24402315]
4. London N, Ceto S, Ranish JA, and Biggins S (2012). Phosphoregulation of Spc105 by Mps1 and PP1 regulates Bub1 localization to kinetochores. *Curr Biol* 22, 900–906. [PubMed: 22521787]
5. Ji Z, Gao H, Jia L, Li B, and Yu H (2017). A sequential multi-target Mps1 phosphorylation cascade promotes spindle checkpoint signaling. *Elife* 6.
6. Faesen AC, Thanasoula M, Maffini S, Breit C, Muller F, van Gerwen S, Bange T, and Musacchio A (2017). Basis of catalytic assembly of the mitotic checkpoint complex. *Nature*.
7. Tipton AR, Ji W, Sturt-Gillespie B, Bekier ME 2nd, Wang K, Taylor WR, and Liu ST (2013). Monopolar spindle 1 (MPS1) kinase promotes production of closed MAD2 (C-MAD2) conformer and assembly of the mitotic checkpoint complex. *J Biol Chem* 288, 35149–35158. [PubMed: 24151075]
8. Hewitt L, Tighe A, Santaguida S, White AM, Jones CD, Musacchio A, Green S, and Taylor SS (2010). Sustained Mps1 activity is required in mitosis to recruit O-Mad2 to the Mad1-C-Mad2 core complex. *J Cell Biol* 190, 25–34. [PubMed: 20624899]
9. Nijenhuis W, Vallardi G, Teixeira A, Kops GJ, and Saurin AT (2014). Negative feedback at kinetochores underlies a responsive spindle checkpoint signal. *Nat Cell Biol* 16, 1257–1264. [PubMed: 25402682]

10. Saurin AT, van der Waal M.S., Medema RH, Lens SM, and Kops GJ (2011). Aurora B potentiates Mps1 activation to ensure rapid checkpoint establishment at the onset of mitosis. *Nat Commun* 2, 316. [PubMed: 21587233]
11. Pinsky BA, Kung C, Shokat KM, and Biggins S (2006). The Ipl1-Aurora protein kinase activates the spindle checkpoint by creating unattached kinetochores. *Nat Cell Biol* 8, 78–83. [PubMed: 16327780]
12. Nijenhuis W, von Castelmur E, Littler D, De Marco V., Tromer E, Vleugel M, van Osch M.H., Snel B, Perrakis A, and Kops GJ (2013). A TPR domain-containing N-terminal module of MPS1 is required for its kinetochore localization by Aurora B. *J Cell Biol* 201, 217–231. [PubMed: 23569217]
13. Chen C, Whitney IP, Banerjee A, Sacristan C, Sekhri P, Kern DM, Fontan A, Kops G, Tyson JJ, Cheeseman IM, and Joglekar AP (2019). Ectopic Activation of the Spindle Assembly Checkpoint Signaling Cascade Reveals Its Biochemical Design. *Curr Biol* 29, 104–119 e110. [PubMed: 30595520]
14. Aravamudhan P, Goldfarb AA, and Joglekar AP (2015). The kinetochore encodes a mechanical switch to disrupt spindle assembly checkpoint signalling. *Nat Cell Biol* 17, 868–879. [PubMed: 26053220]
15. Yuan I, Leontiou I, Amin P, May KM, Soper Ni Chafraidh S., Zlamalova E, and Hardwick KG (2017). Generation of a Spindle Checkpoint Arrest from Synthetic Signaling Assemblies. *Curr Biol* 27, 137–143. [PubMed: 28017606]
16. Leontiou I, London N, May KM, Ma Y, Grzesiak L, Medina-Pritchard B, Amin P, Jeyaprakash AA, Biggins S, and Hardwick KG (2019). The Bub1-TPR Domain Interacts Directly with Mad3 to Generate Robust Spindle Checkpoint Arrest. *Curr Biol* 29, 2407–2414 e2407. [PubMed: 31257143]
17. Di Fiore B, Davey Norman E., Hagting A, Izawa D, Mansfeld J, Gibson Toby J., and Pines J (2015). The ABBA Motif Binds APC/C Activators and Is Shared by APC/C Substrates and Regulators. *Developmental Cell* 32, 358–372. [PubMed: 25669885]
18. Morrow CJ, Tighe A, Johnson VL, Scott MI, Ditchfield C, and Taylor SS (2005). Bub1 and aurora B cooperate to maintain BubR1-mediated inhibition of APC/CCdc20. *J Cell Sci* 118, 3639–3652. [PubMed: 16046481]
19. Ditchfield C, Johnson VL, Tighe A, Ellston R, Haworth C, Johnson T, Mortlock A, Keen N, and Taylor SS (2003). Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. *J Cell Biol* 161, 267–280. [PubMed: 12719470]
20. Santaguida S, Vernieri C, Villa F, Ciliberto A, and Musacchio A (2011). Evidence that Aurora B is implicated in spindle checkpoint signalling independently of error correction. *EMBO J* 30, 1508–1519. [PubMed: 21407176]
21. Vanoosthuysen V, and Hardwick KG (2009). A novel protein phosphatase 1-dependent spindle checkpoint silencing mechanism. *Curr Biol* 19, 1176–1181. [PubMed: 19592249]
22. Hauf S, Cole RW, LaTerra S, Zimmer C, Schnapp G, Walter R, Heckel A, van Meel J, Rieder CL, and Peters JM (2003). The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. *J Cell Biol* 161, 281–294. [PubMed: 12707311]
23. Vader G, Crujisen CW, van Harn T., Vromans MJ, Medema RH, and Lens SM (2007). The chromosomal passenger complex controls spindle checkpoint function independent from its role in correcting microtubule kinetochore interactions. *Mol Biol Cell* 18, 4553–4564. [PubMed: 17699588]
24. King EM, Rachidi N, Morrice N, Hardwick KG, and Stark MJ (2007). Ipl1p-dependent phosphorylation of Mad3p is required for the spindle checkpoint response to lack of tension at kinetochores. *Genes Dev* 21, 1163–1168. [PubMed: 17504936]
25. Haruki H, Nishikawa J, and Laemmli UK (2008). The anchor-away technique: rapid, conditional establishment of yeast mutant phenotypes. *Mol Cell* 31, 925–932. [PubMed: 18922474]
26. Kim T, Moyle MW, Lara-Gonzalez P, De Groot C., Oegema K, and Desai A (2015). Kinetochore-localized BUB-1/BUB-3 complex promotes anaphase onset in *C. elegans*. *J Cell Biol* 209, 507–517. [PubMed: 25987605]




27. Weir JR, Faesen AC, Klare K, Petrovic A, Basilico F, Fischbock J, Pentakota S, Keller J, Pesenti ME, Pan D, et al. (2016). Insights from biochemical reconstitution into the architecture of human kinetochores. *Nature* 537, 249–253. [PubMed: 27580032]
28. Fischer ES, Yu CWH, Bellini D, McLaughlin SH, Orr CM, Wagner A, Freund SMV, and Barford D (2021). Molecular mechanism of Mad1 kinetochore targeting by phosphorylated Bub1. *EMBO Rep*, e52242. [PubMed: 34013668]
29. Vleugel M, Hoek TA, Tromer E, Sliedrecht T, Groenewold V, Omerzu M, and Kops GJ (2015). Dissecting the roles of human BUB1 in the spindle assembly checkpoint. *J Cell Sci* 128, 2975–2982. [PubMed: 26148513]
30. Roy B, Han SJY, Fontan AN, and Joglekar AP (2020). The copy-number and varied strength of MELT motifs in Spc105 balance the strength and responsiveness of the Spindle Assembly Checkpoint. *Elife* 9.
31. Primorac I, Weir JR, Chiroti E, Gross F, Hoffmann I, van Gerwen S, Ciliberto A, and Musacchio A (2013). Bub3 reads phosphorylated MELT repeats to promote spindle assembly checkpoint signaling. *Elife* 2, e01030. [PubMed: 24066227]
32. Piano V, Alex A, Stege P, Maffini S, Stoppiello GA, Huis In 't Veld P.J., Vetter IR, and Musacchio A (2021). CDC20 assists its catalytic incorporation in the mitotic checkpoint complex. *Science* 371, 67–71. [PubMed: 33384373]
33. Lara-Gonzalez P, Kim T, Oegema K, Corbett K, and Desai A (2021). A tripartite mechanism catalyzes Mad2-Cdc20 assembly at unattached kinetochores. *Science* 371, 64–67. [PubMed: 33384372]
34. Overlack K, Primorac I, Vleugel M, Krenn V, Maffini S, Hoffmann I, Kops GJ, and Musacchio A (2015). A molecular basis for the differential roles of Bub1 and BubR1 in the spindle assembly checkpoint. *Elife* 4, e05269. [PubMed: 25611342]
35. Zhang G, Mendez BL, Sedgwick GG, and Nilsson J (2016). Two functionally distinct kinetochore pools of BubR1 ensure accurate chromosome segregation. *Nat Commun* 7, 12256. [PubMed: 27457023]
36. Tromer E, Bade D, Snel B, and Kops GJ (2016). Phylogenomics-guided discovery of a novel conserved cassette of short linear motifs in BubR1 essential for the spindle checkpoint. *Open Biol* 6.
37. Garcia-Rodriguez LJ, Kasciukovic T, Denninger V, and Tanaka TU (2019). Aurora B-INCENP Localization at Centromeres/Inner Kinetochores Is Required for Chromosome Bi-orientation in Budding Yeast. *Curr Biol* 29, 1536–1544 e1534. [PubMed: 31006569]
38. Nakajima Y, Cormier A, Tyers RG, Pigula A, Peng Y, Drubin DG, and Barnes G (2011). Ipl1/Aurora-dependent phosphorylation of Sli15/INCENP regulates CPC-spindle interaction to ensure proper microtubule dynamics. *J Cell Biol* 194, 137–153. [PubMed: 21727193]
39. Larsen NA, Al-Bassam J, Wei RR, and Harrison SC (2007). Structural analysis of Bub3 interactions in the mitotic spindle checkpoint. *Proc Natl Acad Sci USA* 104, 1201–1206. [PubMed: 17227844]
40. Maure JF, Kitamura E, and Tanaka TU (2007). Mps1 kinase promotes sister-kinetochore bi-orientation by a tension-dependent mechanism. *Curr Biol* 17, 2175–2182. [PubMed: 18060784]
41. Biggins S, and Murray AW (2001). The budding yeast protein kinase Ipl1/Aurora allows the absence of tension to activate the spindle checkpoint. *Genes Dev* 15, 3118–3129. [PubMed: 11731476]
42. Rosenberg JS, Cross FR, and Funabiki H (2011). KNL1/Spc105 recruits PP1 to silence the spindle assembly checkpoint. *Curr Biol* 21, 942–947. [PubMed: 21640906]
43. Roy B, Verma V, Sim J, Fontan A, and Joglekar AP (2019). Delineating the contribution of Spc105-bound PP1 to spindle checkpoint silencing and kinetochore microtubule attachment regulation. *J Cell Biol*.
44. Ballister ER, Riegman M, and Lampson MA (2014). Recruitment of Mad1 to metaphase kinetochores is sufficient to reactivate the mitotic checkpoint. *J Cell Biol* 204, 901–908. [PubMed: 24637323]

45. Maldonado M, and Kapoor TM (2011). Constitutive Mad1 targeting to kinetochores uncouples checkpoint signalling from chromosome biorientation. *Nat Cell Biol* 13, 475–482. [PubMed: 21394085]
46. Kuijt TE, Omerzu M, Saurin AT, and Kops GJ (2014). Conditional targeting of MAD1 to kinetochores is sufficient to reactivate the spindle assembly checkpoint in metaphase. *Chromosoma* 123, 471–480. [PubMed: 24695965]
47. Kruse T, Larsen MSY, Sedgwick GG, Sigurdsson JO, Streicher W, Olsen JV, and Nilsson J (2014). A direct role of Mad1 in the spindle assembly checkpoint beyond Mad2 kinetochore recruitment. *EMBO reports* 15, 282–290. [PubMed: 24477933]
48. Vleugel M, Omerzu M, Groenewold V, Hadders MA, Lens SM, and Kops GJ (2015). Sequential multisite phospho-regulation of KNL1-BUB3 interfaces at mitotic kinetochores. *Mol Cell* 57, 824–835. [PubMed: 25661489]
49. Sessa F, Mapelli M, Ciferri C, Tarricone C, Areces LB, Schneider TR, Stukenberg PT, and Musacchio A (2005). Mechanism of Aurora B activation by INCENP and inhibition by hesperadin. *Mol Cell* 18, 379–391. [PubMed: 15866179]
50. Lee S, Thebault P, Freschi L, Beaufile S, Blundell TL, Landry CR, Bolanos-Garcia VM, and Elowe S (2012). Characterization of spindle checkpoint kinase Mps1 reveals domain with functional and structural similarities to tetratricopeptide repeat motifs of Bub1 and BubR1 checkpoint kinases. *J Biol Chem* 287, 5988–6001. [PubMed: 22187426]
51. Mora-Santos MD, Hervas-Aguilar A, Sewart K, Lancaster TC, Meadows JC, and Millar JB (2016). Bub3-Bub1 Binding to Spc7/KNL1 Toggles the Spindle Checkpoint Switch by Licensing the Interaction of Bub1 with Mad1-Mad2. *Curr Biol* 26, 2642–2650. [PubMed: 27618268]
52. Ishihara H, Martin BL, Brautigam DL, Karaki H, Ozaki H, Kato Y, Fusetani N, Watabe S, Hashimoto K, Uemura D, and et al. (1989). Calyculin A and okadaic acid: inhibitors of protein phosphatase activity. *Biochem. Biophys. Res. Commun.* 159, 871–877. [PubMed: 2539153]
53. Etemad B, Kuijt TE, and Kops GJ (2015). Kinetochore-microtubule attachment is sufficient to satisfy the human spindle assembly checkpoint. *Nat Commun* 6, 8987. [PubMed: 26621779]
54. Tauchman EC, Boehm FJ, and DeLuca JG (2015). Stable kinetochore-microtubule attachment is sufficient to silence the spindle assembly checkpoint in human cells. *Nat Commun* 6, 10036. [PubMed: 26620470]
55. Kuhn J, and Dumont S (2019). Mammalian kinetochores count attached microtubules in a sensitive and switch-like manner. *J Cell Biol* 218, 3583–3596. [PubMed: 31492713]
56. Dick AE, and Gerlich DW (2013). Kinetic framework of spindle assembly checkpoint signalling. *Nat Cell Biol* 15, 1370–1377. [PubMed: 24096243]
57. Kops G, and Gassmann R (2020). Crowning the Kinetochore: The Fibrous Corona in Chromosome Segregation. *Trends Cell Biol* 30, 653–667. [PubMed: 32386879]
58. Aravamudhan P, Chen R, Roy B, Sim J, and Joglekar AP (2016). Dual mechanisms regulate the recruitment of spindle assembly checkpoint proteins to the budding yeast kinetochore. *Mol Biol Cell* 27, 3405–3417. [PubMed: 27170178]
59. Bähler Jürg, Wu Jian-Qiu, Longtine Mark S., Shah Nirav G., Mckenzie Amos III, Steever Alexander B., Wach Achim, Philippsen Peter, and Pringle JR (1998). Heterologous modules for efficient and versatile PCR-based gene targeting in *Schizosaccharomyces pombe*. *YEAST* 14, 943–951. [PubMed: 9717240]
60. Scott RJ, Lusk CP, Dilworth DJ, Aitchison JD, and Wozniak RW (2005). Interactions between Mad1p and the nuclear transport machinery in the yeast *Saccharomyces cerevisiae*. *Mol Biol Cell* 16, 4362–4374. [PubMed: 16000377]
61. Kemmler S, Stach M, Knapp M, Ortiz J, Pfannstiel J, Ruppert T, and Lechner J (2009). Mimicking Ndc80 phosphorylation triggers spindle assembly checkpoint signalling. *EMBO J* 28, 1099–1110. [PubMed: 19300438]
62. Khandelia P, Yap K, and Makeyev EV (2011). Streamlined platform for short hairpin RNA interference and transgenesis in cultured mammalian cells. *Proc Natl Acad Sci USA* 108, 12799–12804. [PubMed: 21768390]

63. Gillett ES, Espelin CW, and Sorger PK (2004). Spindle checkpoint proteins and chromosome–microtubule attachment in budding yeast. *The Journal of Cell Biology* 164, 535–546. [PubMed: 14769859]
64. Aravamudhan P, Felzer-Kim I, Gurunathan K, and Joglekar AP (2014). Assembling the protein architecture of the budding yeast kinetochore-microtubule attachment using FRET. *Curr Biol* 24, 1437–1446. [PubMed: 24930965]
65. Joglekar A, Chen R, and Lawrimore J (2013). A Sensitized Emission Based Calibration of FRET Efficiency for Probing the Architecture of Macromolecular Machines. *Cell Mol Bioeng* 6, 369–382. [PubMed: 24319499]
66. Collin P, Nashchekina O, Walker R, and Pines J (2013). The spindle assembly checkpoint works like a rheostat rather than a toggle switch. *Nat Cell Biol* 15, 1378–1385. [PubMed: 24096242]
67. Gupta A, Evans RK, Koch LB, Littleton AJ, and Biggins S (2018). Purification of kinetochores from the budding yeast *Saccharomyces cerevisiae*. *Methods in cell biology* 144, 349–370. [PubMed: 29804677]
68. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, et al. (2012). Fiji: an open-source 944 platform for biological-image analysis. *Nat Methods* 9, 676–682. [PubMed: 22743772]

**Highlights**


- Aurora B cannot activate the SAC because it cannot phosphorylate Knl1 'MELT' motifs.
- Aurora B promotes SAC signaling by phosphorylating Bub1.
- Aurora B activity promotes Mad1 recruitment via Bub1.
- Aurora B activity in SAC signaling also requires the ABBA motif of Bub1.



**Figure 1. Dissection of the regulatory role of the Mps1 kinase in the SAC signaling cascade using the ‘eSAC’ system.**

(A) A simplified schematic of the SAC signaling cascade in budding yeast. Black arrows represent regulated recruitment of downstream signaling proteins; black lines represent constitutive protein-protein interactions. The ‘Mps1’ label over an arrow signifies phosphoregulation of the protein recruitment step by Mps1. Gray arrow represents the assembly of sub-complexes into the mitotic checkpoint complex. (B) The ectopic activation of the SAC signaling cascade (simplified on the left hand) by the rapamycin-induced dimerization of Mps1–2xFkbp12 with a cytosolic fragment of Spc105 containing just

one MELT motif (GFP-Spc105<sup>120-128</sup>-Frb). Graphs on the right show the quantitation of cellular DNA content using flow cytometry over 4 hours after the addition of rapamycin to the growth media. Strain genotype is indicated at the top of each graph. Grey, red and dashed blue lines show cytometry results for DMSO-treated, rapamycin-treated wild-type and *mad1* cells respectively. Representative micrographs of yeast cells expressing the indicated, fluorescently labeled proteins (right). Notice that the cytosolic GFP-Spc105<sup>2-128</sup>-Frb displays faint kinetochore colocalization in rapamycin-treated cells, likely because Mps1 localizes to bioriented kinetochores<sup>14</sup>. Scale bar~3.2 $\mu$ m. (C) Top: Domain organization of full length Bub1 (Bub1<sup>FL</sup>) and its middle domain in budding yeast. Bottom left: Schematic of the potential effects of the rapamycin-induced dimerization of Mps1-Frb with Bub1-2xFkbp12. Bottom right: Graphs show flow cytometry of DMSO-treated (black lines) and rapamycin-treated (red lines) cells with the indicated genotype. (D) Top: Flow cytometry panels showing effects of rapamycin-induced dimerization of Mps1-Frb with the Mad1-2xFkbp12 in wild-type, in absence of Mad3, in presence of *spc105-6A*, in absence of Bub3 and in presence of *bub1<sup>-abba</sup>*. Plots with black, red and cyan lines indicate cells treated with DMSO (control), rapamycin and nocodazole respectively. Middle: Domain organization of Mad1-CTD (amino acid 426-749) in budding yeast. Bottom: In left, a partial schematic of SAC cascade is shown. In right the potential effects of the rapamycin-induced dimerization of Mps1-Frb with the Mad1-CTD-2xFkbp12 or Mad1-CTD<sup>4A</sup> (T624A, T704A, T737A, T739A)-2xFkbp12 are shown. Color scheme as in B-C. (E) Localization of ectopically expressed GFP-Mad3 in cells arrested in mitosis due to nocodazole treatment. Note that in nocodazole-treated yeast cells typically contain two kinetochore clusters. The larger cluster is proximal to the spindle pole bodies (not visualized), and kinetochores within this cluster are attached to short microtubule stubs. The smaller cluster is distal to the spindle pole bodies (asterisk), and the kinetochores within this cluster are unattached<sup>58</sup>. Scale bars ~ 3.2  $\mu$ m. See also Figure S1, Table S1, and Data S1A.




**Figure 2. Rapamycin-induced dimerization of Aurora B/Ipl1 with Bub1 and Mad1, but not MELT motifs, leads to ectopic SAC activation.**

(A) Localization of Ipl1-mCherry and yeast kinetochores (visualized with Spc105<sup>222::GFP</sup>) in yeast cells arrested in mitosis due to nocodazole treatment. Asterisks mark the cluster of unattached kinetochores in each cell. Scale bar ~ 3.2 $\mu$ m. (B) Left: Potential effects of the rapamycin-induced dimerization of Ipl1-Frb with the indicated SAC signaling protein. Middle: flow cytometry analysis of DMSO or Rapamycin-treated cultures of indicated strains. Color scheme as in Fig. 1. Right: Micrographs showing morphology of rapamycin-treated cells expressing Ipl1-Frb and either Bub1-2XFkbp12 or Mad1-2XFkbp12. Scale bar ~ 3.2 $\mu$ m. (C) Top left: Flow cytometry analysis following rapamycin induced dimerization of Bub1-1xFkbp12 with Ipl1<sup>WT</sup> (red) or Ipl1<sup>K133R</sup>-Frb-GFP (dashed blue). Top right: Representative micrographs of yeast cells expressing Dsn1-mCherry after treatment with DMSO or rapamycin. Scale bar ~ 3.2 $\mu$ m. Bottom left: Flow cytometry panel showing effects of rapamycin induced dimerization of Ipl1-Frb with GFP-bub1<sup>368-609</sup>-2xFkbp12

(Color scheme: DMSO, grey; WT, red; -abba, dashed blue). Bottom right: Representative micrographs of yeast cells expressing Ndc80-mCherry and GFP-bub1<sup>368-609</sup>-2xFkbp12 after treatment with DMSO, rapamycin and nocodazole. Scale bar~3.2μm. (D) Dissection of the contributions of Bub1-mediated recruitment of Mad1 and Cdc20 in ectopic SAC signaling driven by Mps1 using Bub1 point mutants. 2xFkbp12-tagged Bub1 mutants (indicated at the top of each flow cytometry panel) expressed from the genomic Bub1 locus. (E) Flow cytometric analysis of the effect of rapamycin induced dimerization of Ipl1 and Mad1 in absence of Bub1 (*bub1* , top), in presence of *bub1*<sup>-abba</sup> (middle) and in presence of *bub1*<sup>T485A, T509A, T518A</sup> (bottom) on the cell cycle. (F) Left: Tetrad dissection of diploids with the indicated genotype. The plate with *SPC105*/<sub>2</sub> , *spc105*<sup>RASA</sup> were imaged after 2 days (left) and 5 days (middle) before replica plating. The plate with *SPC105*/<sub>2</sub> , *spc105*<sup>RASA</sup> , *bub1*<sup>-abba</sup> was replica plated after 2 days of incubation and then imaged on the 3<sup>rd</sup> day. The growth rate of segregants expressing *spc105* , *spc105*<sup>RASA</sup> , *bub1*<sup>-abba</sup> (red circles) is similar to wildtype segregants. The numbers of inviable segregants for *spc105* , *spc105*<sup>RASA</sup> , *bub1*<sup>-abba</sup> and inviable or micro-colony forming segregants (blue squares) for *spc105* , *spc105*<sup>RASA</sup> are consistent with the probabilities predicted by the random segregation of three and two genes (0.33 and 0.5) respectively. Right: Flow cytometric analysis of cell cycle progression in nocodazole-treated cells carrying the indicated mutations. See also Figure S2, Table S1, Table S2, Data S1B.






**Figure 3. Rapamycin-induced dimerization of INCENP<sup>818-918</sup> with Bub1 and Mad1, but not with MELT motifs, leads to ectopic SAC activation in HeLa cells.**

(A) Left: Schematic of the eSAC system designed to test the roles of Aurora B kinase activity in the core SAC signaling cascade in HeLa cells. Right: A representative micrograph from a time-lapse experiment showing the variable expression of Frb-mCherry-INCENP<sup>818-918</sup>. Scale bar ~ 8.25 microns. (B) Schematic at the top displays the domain organization of the eSAC phosphodomain. Scatter plots show the correlation between time in mitosis for a given cell and the average mCherry fluorescence at the beginning of mitosis for that cell. Each gray dot represents one cell (n = 520, 787, 840 respectively, data pooled from 2 experiments). The blue circles represent the mean of data binned according to the mCherry signal; the horizontal and vertical lines represent the s.e.m.

For the Bub1 and Mad1-CTD fragments, the solid blue lines display a four-parameter sigmoidal fit to the binned mean values;  $R^2$  values = 0.2, 0.2, respectively. (C) Western blot probing for the phosphorylation of the MEIT motif by Aurora B. Also see Figure S3C. (D) Bar graphs display the maximal response predicted by the 4-parameter sigmoidal fit from B. Vertical lines display the 95% confidence interval for the estimated maximal response. For comparison, the maximal response from eSAC systems comprised of the same three eSAC phosphodomains dimerized with the Mps1 kinase domain is also plotted (data marked by asterisks reproduced from <sup>13</sup>). Vertical lines for the M3-M3-Mps1 dimerization represent the standard deviation of the bin corresponding to the peak eSAC response. This representation was made necessary by the non-monotonic nature of the dose-response data. (E) The contributions of the Bub3- and Cdc20-binding domains in Bub1 to the observed eSAC activity driven by either the Mps1 or Aurora B ( $n = 2635, 614$ , for the top panel and  $n = 752, 1524$  for the bottom panel;  $R^2$  values = 0.44, 0.24, 0.51, and 0.16 respectively pooled from at least 2 experiments). The domain organization of the phosphodomain is displayed in the schematic at the top. Data presented as in B. (F) Comparison of the maximal response elicited from the indicated phosphodomains by either the Mps1 kinase domain or INCENP<sup>818-918</sup> (predicted mean  $\pm$  95% confidence intervals). See also Figure S3, Data S1C–E, Video S1 and Video S2.



**Figure 4. Aurora B contribution to kinetochore-based SAC signaling.**

(A) Scatter plot displays the duration of the mitotic arrest. Experimental treatments are indicated below each bar. (n = 92, 48, 43, 44, 41, experiment performed twice). Cells treated with B56 RNAi and ZM447439 both exited from mitosis very rapidly without assuming the rounded morphology. In this case, entry of the cell into mitosis was visually identified by the release of surface adhesion along with concurrent condensation of Histone H2B signal (in one experiment). Exit from mitosis was identified from the re-spreading off the cell over the surface (micrograph montage at the bottom, also see Video S3). Scale bar ~ 9 microns. (B) Table summarizes the results from the eSAC experiments performed both

in yeast and human cells. (C) The proposed mechanism of the direct role of Aurora B kinase activity in SAC signaling. (D) Aurora B-mediated promotion of MCC generation may enable kinetochores with syntelic attachments to continue to produce MCC and thus delay anaphase onset. See also Video S3.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

## KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
<b>Antibodies</b>		
Mouse $\alpha$ -Hec1 9G3.23	Novus Biological	NB100-338
Mouse $\alpha$ -GFP	Takara	JL-8 [Living Colors]
Mouse $\alpha$ -Ds-Red	SantaCruz Biotechnologies	sc-390909
Mouse $\alpha$ - $\beta$ Tubulin	Millipore Sigma	T7816
Rabbit $\alpha$ -Fkbp12	Abcam	ab2918
Rabbit $\alpha$ -PhosphoMELT	48	N/A
Mouse $\alpha$ -Cdc20	Santa Cruz Biotechnologies	sc-13162
Mouse $\alpha$ -Mad2	Millipore Sigma	MABE866
Mouse $\alpha$ -Apc3	BD Biosciences	610455
Goat $\alpha$ -Rabbit HRP conjugated	Millipore Sigma	A4914
Goat $\alpha$ -Mouse HRP conjugated	Millipore Sigma	A4416
Goat $\alpha$ -Mouse 488	Life technologies	A11001
<b>Yeast strains</b>		
For yeast strains used in this study, please see Table S3	This paper	AJY#
<b>Recombinant DNA/Plasmids</b>		
For plasmids used in this study, please see Table S3	This paper	pAJ#
<b>Chemicals</b>		
Nocodazole	Thermo-Fisher Scientific	AC358240100
Propidium Iodide (PI)	Millipore Sigma	P4864
Rapamycin	Thermo-Fisher Scientific	NC9362949
RNase	Millipore Sigma	10109142001
Phenylmethylsulfonyl fluoride	Millipore Sigma	P7626
Sodium pyrophosphate	Millipore Sigma	221368
Sodium beta-glycerophosphate	Millipore Sigma	G5422
Sodium orthovanadate	Millipore Sigma	S6508
Sodium fluoride	Millipore Sigma	450022
Microcystin-LR	Calbiochem	475815
1-NM-PP1	Millipore Sigma	529581
Doxycycline	Thermo-Fisher Scientific	AAJ67043AD
GSK-923295	Thermo-Fisher Scientific	50-190-4805
Calyculin A	Thermo-Fisher Scientific	PHZ1044
Reversine	Thermo-Fisher Scientific	50-187-3070
GSK-923295	Thermo-Fisher Scientific	50-196-8004
ZM447439	Thermo-Fisher Scientific	50-827-9
RO-3306	Thermo-Fisher Scientific	R020150MG
Thymidine	Millipore Sigma	50-89-5

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Ponceau S solution	Millipore Sigma	P7170
Thermo Scientific™ StartingBlock™ (PBS) Blocking Buffer	Thermo-Fisher Scientific	PI37578
Molecular Probes™ ProLong™ Diamond Antifade Mountant	Thermo-Fisher Scientific	P36961
Concanavalin A	Thermo-Fisher Scientific	ICN15071001
<b>Critical commercial assays</b>		
Bio-Rad Protein Assay Dye Reagent Concentrate	Bio-Rad	500-0006
ChromoTek GFP-Trap® Agarose	Proteintech	gta-20
Pierce™ Protein G Agarose	Thermo-Fisher Scientific	20399
<b>Oligonucleotides</b>		
B56a UGAAUGAACUGGUUGAGUA[dT][dT]	Millipore Sigma	N/A
B56b GAACAAUGAGUAUAUCCUA[dT][dT]	Millipore Sigma	N/A
B56c GGAAGAUGAACCAACGUUA[dT][dT]	Millipore Sigma	N/A
B56d UGACUGAGCCGGUAAUUGU[dT][dT]	Millipore Sigma	N/A
B56e GCACAGCUGGCAUUAUGUA[dT][dT]	Millipore Sigma	N/A
<b>Software and algorithms</b>		
Graphpad Prism, Prism Version 8	Graphpad software Inc.	<a href="https://www.graphpad.com/scientific-software/prism/">https://www.graphpad.com/scientific-software/prism/</a>
ImageJ (Fiji)	68	<a href="https://imagej.net/Fiji/Downloads">https://imagej.net/Fiji/Downloads</a>
Matlab, R2019b	Mathworks	<a href="https://www.mathworks.com/products/matlab.html">https://www.mathworks.com/products/matlab.html</a>
Metamorph	Molecular devices	<a href="https://www.moleculardevices.com/products/cellular-imaging-systems/acquisition-and-analysis-software/metamorph-microscopy">https://www.moleculardevices.com/products/cellular-imaging-systems/acquisition-and-analysis-software/metamorph-microscopy</a>
Flowjo, FlowJo_v10.7.1_CL	BD Biosciences,	<a href="https://www.flowjo.com/">https://www.flowjo.com/</a>
Adobe Illustrator, version 2021	Adobe creative cloud	<a href="https://www.adobe.com/products/illustrator.html">https://www.adobe.com/products/illustrator.html</a>
<b>Other</b>		
Lipofectamine 3000	Life Technologies	L3000008
Lipofectamine RNAiMAX	Life Technologies	13778075
Precision Plus Protein Dual Color Standards	Bio-Rad	1610374